Literature DB >> 17949478

Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2).

A Sahni1, P J Simpson-Haidaris, S K Sahni, G G Vaday, C W Francis.   

Abstract

BACKGROUND: Fibroblast growth factor (FGF)-2 is a critical growth factor in normal and malignant cell proliferation and tumor-associated angiogenesis. Fibrinogen and fibrin bind to FGF-2 and modulate FGF-2 functions. Furthermore, we have shown that extrahepatic epithelial cells are capable of endogenous production of fibrinogen.
OBJECTIVE: Herein we examined the role of fibrinogen and FGF-2 interactions on prostate and lung adenocarcinoma cell growth in vitro.
METHODS: Cell proliferation was measured by (3)H-thymidine uptake and the specificity of FGF-2-fibrinogen interactions was measured using wild-type and mutant FGF-2s, fibrinogen gamma-chain (FGG) RNAi and co-immunoprecipitation. Metabolic labeling, immunopurification and fluorography demonstrated de novo fibrinogen production.
RESULTS: FGF-2 stimulated DU-145 cell proliferation, whereas neither FGF-2 nor fibrinogen affected the growth of PC-3 or A549 cells. Fibrinogen augmented the proliferative effect of FGF-2 on DU-145 cells. The role of fibrinogen in FGF-2-enhanced DNA synthesis was confirmed using an FGF-2 mutant that exhibits no binding affinity for fibrinogen. FGG transcripts were present in PC-3, A549 and DU-145 cells, but only PC-3 and A549 cells produced detectable levels of intact protein. RNAi-mediated knockdown of FGG expression resulted in decreased production of fibrinogen protein and inhibited (3)H-thymidine uptake in A549 and PC-3 cells by 60%, which was restored by exogenously added fibrinogen. FGF-2 and fibrinogen secreted by the cells were present in the medium as a soluble complex, as determined by coimmunoprecipitation studies.
CONCLUSIONS: These data indicate that endogenously synthesized fibrinogen promotes the growth of lung and prostate cancer cells through interaction with FGF-2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17949478     DOI: 10.1111/j.1538-7836.2007.02808.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  78 in total

1.  Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers.

Authors:  Ana Custodio; Antonio J López-Farré; José J Zamorano-León; Petra J Mateos-Cáceres; Carlos Macaya; Trinidad Caldés; Miguel de la Hoya; Elena Olivera; Javier Puente; Eduardo Díaz-Rubio; Pedro Pérez-Segura
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-07       Impact factor: 4.553

2.  Influence of Stromal Components on Lung Cancer Carcinogenesis.

Authors:  Laurie A Shuman Moss; William G Stetler-Stevenson
Journal:  J Carcinog Mutagen       Date:  2013-06-25

3.  Prognostic significance of preoperative fibrinogen in patients with colon cancer.

Authors:  Zhen-Qiang Sun; Xiao-Na Han; Hai-Jiang Wang; Yong Tang; Ze-Liang Zhao; Yan-Li Qu; Rui-Wei Xu; Yan-Yan Liu; Xian-Bo Yu
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

4.  FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma.

Authors:  Zhi Shang; Xiaomin Niu; Kewei Zhang; Zhi Qiao; Sha Liu; Xiaoteng Jiang; Chengxi Cao; Shun Lu; Hua Xiao
Journal:  J Mol Med (Berl)       Date:  2019-11-28       Impact factor: 4.599

5.  FGB and FGG derived from plasma exosomes as potential biomarkers to distinguish benign from malignant pulmonary nodules.

Authors:  Muyu Kuang; Yizhou Peng; Xiaoting Tao; Zilang Zhou; Hengyu Mao; Lingdun Zhuge; Yihua Sun; Huibiao Zhang
Journal:  Clin Exp Med       Date:  2019-10-01       Impact factor: 3.984

6.  Characterization of the chemotactic and mitogenic response of SMCs to PDGF-BB and FGF-2 in fibrin hydrogels.

Authors:  Areck A Ucuzian; Luke P Brewster; Andrea T East; Yongang Pang; Andrew A Gassman; Howard P Greisler
Journal:  J Biomed Mater Res A       Date:  2010-09-01       Impact factor: 4.396

7.  Combined fibrinogen concentration and neutrophil-lymphocyte ratio as a prognostic marker of gastric cancer.

Authors:  Takaaki Arigami; Yoshikazu Uenosono; Daisuke Matsushita; Shigehiro Yanagita; Yasuto Uchikado; Yoshiaki Kita; Shinichiro Mori; Yuko Kijima; Hiroshi Okumura; Kosei Maemura; Sumiya Ishigami; Shoji Natsugoe
Journal:  Oncol Lett       Date:  2015-12-22       Impact factor: 2.967

8.  The preoperative elevated plasma fibrinogen level is associated with the prognosis of hilar cholangiocarcinoma.

Authors:  Xi-Wen Ye; Hai-Jie Hu; Xian-Ze Xiong; Jiong Lu; Nan-Sheng Cheng
Journal:  Surg Today       Date:  2021-03-02       Impact factor: 2.549

9.  Pretreatment plasma fibrinogen as an independent prognostic indicator of prostate cancer patients treated with androgen deprivation therapy.

Authors:  Y Wang; W Yin; Z Wang; J Huang; J Pan; Y Zhu; F Xu; X Shao; J Sha; Y Cai; Q Liu; B Dong; W Xue; Y Huang
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-03-08       Impact factor: 5.554

10.  The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial.

Authors:  V Seebacher; S Polterauer; C Grimm; H Husslein; H Leipold; K Hefler-Frischmuth; C Tempfer; A Reinthaller; L Hefler
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.